Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinalbuphine Sebacate for Postoperative Pain in Shoulder Arthroscopy
NCT05115955Phase 4Completed
- Sponsor
- Tri-Service General Hospital
- Start
- Nov 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dinalbuphine sebacate in postoperative pain (2 arms), sponsored by Tri-Service General Hospital. Primary endpoints: Acute postoperative pain intensity at 1 day and Brief Pain Inventory at 1 day. Started Nov 2021; status: completed.
02
Drugs
dinalbuphine sebacate
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05115955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05115955.